In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials The US Food and Drug Administration (FDA) on Thursday released an alert and summary of findings from two halted ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Pembrolizumab in early triple-negative breast cancer shows irAEs similar to KEYNOTE-522, with endocrinopathies and severe gastrointestinal effects being prevalent. The study involved a diverse patient ...

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...

Merck (NYSE:MRK) plans to present more than 100 oncology abstracts at the 2026 ASCO Annual Meeting. The company will share ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.